The participation of clinical pharmacists in the treatment of patients with central nervous system infection can improve the effectiveness and appropriateness of anti-infective treatments: a retrospective cohort study

Cheng, Jie; Dang, ChuanDong; Li, Xiao; Wang, JianJun; Huang, Xin; Li, Yan; Cui, XueYan

doi:10.3389/fphar.2023.1226333

Cited by 2 publications

(1 citation statement)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the “Clinical Pharmacist” node, the most relevant literature was a study on drug management in nursing homes, highlighting the contribution of clinical pharmacists in reducing the medication error rate ( 20 ). The latest literature introduces clinical pharmacists in central nervous system infection (CNSI) for the treatment of infections in patients with positive effects ( 21 ). The highly cited literature was a randomized controlled trial that explored the impact of a collaborative approach on prescription quality in geriatric inpatients ( 22 ).…”

Section: Resultsmentioning

confidence: 99%

Evolutionary trend analysis of the pharmaceutical management research field from the perspective of mapping the knowledge domain

Shen,

Wei,

Guo

et al. 2024

Front. Health Serv.

View full text Add to dashboard Cite

BackgroundPharmaceutical management is a new frontier subject between pharmacy, law and management, and related research involves the whole process of drug development, production, circulation and use. With the development of medical systems and the diversification of patients’ drug needs, research in the field of pharmaceutical management is becoming increasingly abundant. To clarify the development status of this field, this study conducted a bibliometric analysis of relevant literature in the field based on the knowledge graph method for the first time and explored the evolutionary trends of research hotspots and frontiers.MethodsLiterature was obtained from the Web of Science Core Collection database. CiteSpace 6.2.R4 (Advanced), VOSViewer, Scimago Graphica, Pajek and the R programming language were used to visualize the data.ResultsA total of 12,771 publications were included in the study. The publications in the field of pharmaceutical management show an overall increasing trend. In terms of discipline evolution, early research topics tended to involve the positioning of pharmacists and pharmaceutical care and the establishment of a management system. From 2000 to 2005, this period tended to focus on clinical pharmacy and institutional norms. With the development of globalization and the market economy, research from 2005 to 2010 began to trend to the fields of drug markets and economics. From 2010 to 2015, research was gradually integrated into health systems and medical services. With the development of information technology, after 2015, research in the field of pharmaceutical management also began to develop in the direction of digitalization and intelligence. In light of the global pandemic of COVID-19, research topics such as drug supply management, pharmaceutical care and telemedicine services under major public health events have shown increased interest since 2020.ConclusionBased on the knowledge mapping approach, this study provides a knowledge landscape in the field of pharmaceutical management research. The results showed that the reform of pharmacy education, the challenge of drug management under the COVID-19 pandemic, digital transformation and the rise of telemedicine services were the hot topics in this field. In addition, the research frontier also shows the broad prospects of the integration of information technology and pharmaceutical management, the practical value of precision pharmaceutical services, the urgent need of global drug governance, and the ethical and legal issues involved in the application of artificial intelligence technology in drug design, which points out the direction for the future development of pharmaceutical practice.

show abstract

Section: Resultsmentioning

confidence: 99%

Evolutionary trend analysis of the pharmaceutical management research field from the perspective of mapping the knowledge domain

Shen,

Wei,

Guo

et al. 2024

Front. Health Serv.

View full text Add to dashboard Cite

show abstract

Toxic epidermal necrolysis caused by phenobarbital: a case report and literature review

Cheng,

Li,

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

BackgroundToxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) are rare, life-threatening immunologic reactions. Previous relevant literature has provided limited information regarding this disease’s genetic susceptibility and management principles.ObjectivesThis study aimed to describe a phenobarbital-induced TEN case report with HLA-B*15:02 and HLA-B*58:01 negative, CYP2C19*1/*2. In addition, we revised the existing literature on phenobarbital-induced SJS/TEN to explore its clinical characteristics.MethodsWe describe a woman undergoing treatment with Phenobarbital for status epilepticus who developed classic cutaneous findings of TEN. A systematic search was conducted in the PubMed, Medline, WanFang, and CNKI databases from 1995 to 2023. The search terms used were “Stevens-Johnson Syndrome,” “Toxic Epidermal Necrolysis,” and “Phenobarbital.”ResultsWe report a case of TEN resulting from phenobarbital; it tested negative for the HLA-B*15:02 and HLA-B*58:01 allele and CYP2C19*1/*2 intermediate metabolism. Supportive treatment with steroids and antihistamines resulted in complete resolution of the skin lesions and improvement in clinical symptoms after 14 days. Physicians and clinical pharmacists should be aware of these potential phenobarbital-related adverse events and closely monitor patients with first-time use of phenobarbital. Among 19 cases were identified in the literature, with 11 (57.9%) cases of SJS, 6 (31.6%) cases of TEN, and 2 (7.2%) cases of SJS-TEN/DRESS overlap. A total of 5 (26.3%) did not survive, of which 4 (21.1%) were under 12 years old and 1 (5.3%) was over 12 years old.ConclusionPhenobarbital-induced SJS/TEN may still occur in patients who test negative for HLA-B*15:02 and HLA-B*58:01, CYP2C19*1/*2. Most cutaneous adverse events occur early in the course of Phenobarbital therapy and should be closely monitored early in the course of treatment. In addition, Phenobarbital should be used with caution in patients with a history of asthma and allergy to antipyretics and analgesics.

show abstract

The participation of clinical pharmacists in the treatment of patients with central nervous system infection can improve the effectiveness and appropriateness of anti-infective treatments: a retrospective cohort study

Cited by 2 publications

References 51 publications

Evolutionary trend analysis of the pharmaceutical management research field from the perspective of mapping the knowledge domain

Evolutionary trend analysis of the pharmaceutical management research field from the perspective of mapping the knowledge domain

Toxic epidermal necrolysis caused by phenobarbital: a case report and literature review

Contact Info

Product

Resources

About